Stocks to buy: ITC, Indigo Paints among 10 stocks Sharekhan gives a 'buy' on after Q4 results; check out target price
Domestic brokerage Sharekhan has recommended buying eight stocks across different sectors from cement, and paint to Fast Moving Consumer Goods (FMCG). The revision comes at a time when all listed companies are coming up with their Q4 results.
Here are 10 stocks Sharekhan is upbeat on:
(DISCLAIMER: The views and investment tips expressed by investment experts on zeebiz.com are their own and not those of the website or its management. zeebiz.com advises users to check with certified experts before taking any investment decisions.)
The Ramco Cements
The Ramco Cements
Sharekhan has retained 'buy' on the Ramco Cements with a revised target price of Rs 1,010 apiece, led by a downward revision in estimates and considering a strong earnings growth profile over FY2024-FY2026E.
Bharat Electronics Ltd (BEL)
Bharat Electronics Ltd (BEL)
The brokerage iterated a 'buy' on BEL with a revised target price of Rs 325 apiece. As per Sharekhan, Q4 numbers were robust with revenues of Rs. 8564 crore, up 32 per cent year-on-year (YoY).
Grasim
Grasim
With a buy' on Grasim Sharekhan revised its target price to Rs 2,850 as Q4 reported marginally better-than-expected standalone operational performance.
Indigo Paints
Indigo Paints
Sharekhan has given a 'buy' on Indigo Paints with an unchanged target price of Rs. 1,850 apiece.
ITC
ITC
With a buy' on ITC Sharekhan maintained its target price to Rs 515 after the FMCG giant reported its Q4 numbers.
Jubilant FoodWorks
Jubilant FoodWorks
The brokerage has upgraded Jubilant Foodworks to 'buy' from 'hold' with a revised target price of Rs 570 on the back of better earnings visibility, focus on achieving profitable growth in India business, and attractive valuation at 22x and 19x its FY25E and FY26E consolidated EV/EBIDTA.
Sun Pharmaceutical Industries
Sun Pharmaceutical Industries
With a buy' on Sun Pharmaceutical Industries, Sharekhan revised its target price to Rs 1,800 as it believes its superior margin profile and healthy cash balance to enable it to trade at a premium valuation to its peers thus ascribing a PE of 33x on FY26E to arrive at a price target.
Strides Pharma Science
Strides Pharma Science
Sharekhan maintained a 'buy' rating on Strides Pharma Science with an upward revision in target price to Rs 1,050 from Rs 900. As per the brokerage, Q4 numbers were healthy on all fronts, led by higher sales in the North American region due to the launch of Icosapent and Suprep.
Zydus Lifesciences
Zydus Lifesciences
The brokerage has maintained a 'buy' on Zydus Lifesciences with an upward revision in target price to Rs 1200. It expects EBITDA margins to rise 100 bps every year to 29 per cent by FY26E despite R&D spending, driven by a healthy product mix.
Balkrishna Industries
Balkrishna Industries
Sharekhan has upgraded its rating from 'hold' to 'buy' on Balkrishna Industries with a revised target price of Rs 3,195 in expectation of demand revival, sustenance of EBITDA margin, and its market share gain strategies.